Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | YARS1 | P54577 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372552 | 0.89 | OPRD1 (0.56) | OPRD1OPRM1OPRK1 | |
| SCHEMBL8975673 | 0.89 | SLC7A5 (0.60) | OPRD1OPRM1OPRK1SLC7A5YARS1 | |
| SCHEMBL8975669 | 0.89 | SLC7A5 (0.60) | OPRD1OPRM1OPRK1SLC7A5YARS1 | |
| SCHEMBL10974111 | 0.89 | SLC7A5 (0.60) | OPRD1OPRM1OPRK1SLC7A5YARS1 | |
| SCHEMBL11406587 | 0.87 | OPRD1 (0.50) | OPRD1OPRM1OPRK1SLC7A5YARS1 | |
| SCHEMBL8673162 | 0.87 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL8673006 | 0.87 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL9724057 | 0.87 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL10716732 | 0.85 | OPRD1 (0.61) | OPRD1OPRM1OPRK1SLC7A5YARS1 | |
| SCHEMBL10621141 | 0.85 | OPRD1 (0.61) | OPRD1OPRM1OPRK1SLC7A5YARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0001684-B1 | TETRAPEPTIDES, METHODS FOR THEIR PREPARATION AND THEIR USE IN ANALGESIC COMPOSITIONS | ELI LILLY AND COMPANY (US) | 1981-09-02 | — | — | EP | claimed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
| US-6740639-B1 | L-TYROSYL-D-ALANYL-GLYCYL-N-METHYLPHENYLALANYL-GLYCYL -ISOPROPYLAMIDE AND CYCLODEXTRIN DERIVATIVES; ANALGESIC, ANTIINFLAMMATORY, NONADDICTIVE PROPERTIES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2004-05-25 | — | — | US | disclosed |
| EP-0030847-A2 | Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1981-06-24 | — | — | EP | disclosed |
| US-4261883-A | OLIGOPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1981-04-14 | — | — | US | disclosed |
| US-4261883-A | OLIGOPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRD1 3100/4885OPRM1 2317/4885OPRK1 2737/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | OPRD1 3859/4885OPRM1 3352/4885OPRK1 3229/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | OPRD1 3859/4885OPRM1 3352/4885OPRK1 3229/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRD1 3100/4885OPRM1 2317/4885OPRK1 2737/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | OPRD1 2871/4885OPRM1 1535/4885OPRK1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.